Shanghai Fosun Pharmaceutical : 2020 THIRD QUARTERLY REPORT（H SHARE）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2020 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report for 2020 of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'', together with its subsidiaries, collectively the ''Group'') (the ''2020 Third Quarterly Report''). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.

By Order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the People's Republic of China

29 October 2020

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

- 1 -

1. IMPORTANT NOTICE

1. The board of directors (the ''Board'') and the supervisory committee (the ''Supervisory Committee'') of the Company and its directors, supervisors and senior management warrant that the 2020 Third Quarterly Report of the Group does not contain any false information, misleading statements or material omission and severally and jointly accept legal responsibility for the truthfulness, accuracy and completeness of the contents contained herein.
2. All directors of the Company attended the Board meeting to review the 2020 Third Quarterly Report of the Group.
3. Chen Qiyu, the person in charge of the Company, Guan Xiaohui, the Chief Financial Officer, and Chen Zhanyu, the Director of the Accounting Department (Accounting Officer) duly declare that they warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2020 Third Quarterly Report of the Group.
4. The 2020 Third Quarterly Report of the Group has not been audited.

- 2 -

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

2.1 Major financial information
			Unit: Yuan	Currency: RMB
		30 September 2020	31 December 2019	Ratio of change (%)
Total assets		80,547,989,215.24	76,119,645,663.32	5.82
Net assets attributable to shareholders of the listed company		33,083,709,544.28	31,888,066,063.03	3.75
				Period-on-period
		Jan - Sept 2020	Jan - Sept 2019	change (%)
Net cash flow generated from operating activities		2,453,135,520.00	2,328,355,784.17	5.36
				Period-on-period
		Jan - Sept 2020	Jan - Sept 2019	change (%)
Operating revenue		22,102,744,284.03	21,227,618,679.11	4.12
Net profit attributable to shareholders of the listed company		2,478,980,552.00	2,063,704,147.99	20.12
Net profit attributable to shareholders of the listed company		2,059,539,441.46	1,722,388,028.34	19.57
after deducting extraordinary gain or loss
Weighted average return on net assets (%)		7.52	7.21	Increase by 0.31
				percentage point
Basic earnings per share (RMB/share)		0.97	0.81	19.75
Diluted earnings per share (RMB/share)		0.97	0.81	19.75
Extraordinary gain or loss items and amounts
			Unit: Yuan	Currency: RMB
Items		Jul - Sept 2020	Jan - Sept 2020
Gain or loss on disposal of non-current assets		59,844,008.57	148,673,855.03
Government grant included in profit or loss for the current period (excluding	6,590,725.79	63,073,671.90
government grant closely related to the Company's normal operation, and entitled in
fixed amounts or quantities on a continuous basis according to national standards)
Profit or loss arising from changes in the fair value of holding held-for-trading financial	-21,836,656.22	418,849,091.49
assets, derivative financial assets, held-for-trading financial liabilities and derivative
financial liabilities, and investment income from disposal of held-for-trading financial
assets, derivative financial assets, held-for-trading financial liabilities, derivative
financial liabilities and other debt investments, except effective hedging business
related to the Company's normal operations
Non-operating income and expenses other than those stated above		-9,365,192.57	-29,708,642.14
Other profit or loss items that fall within the meaning of extraordinary gain or loss	-	-18,528,108.93
Impact on minority interests (after tax)		-13,347,990.54	-44,045,903.53
Effect of income tax		-12,806,024.25	-118,872,853.28
Total		9,078,870.78	419,441,110.54

- 3 -

2.2 Total number of shareholders, the shareholding status of the Top 10 shareholders and the Top 10 tradable shareholders (or unrestricted shareholders) of the Company at the end of the Reporting Period

						Unit: Share
Total number of shareholders						324,777
The shareholding status of the Top 10 shareholders
	Shareholding	Percentage	Number of	Shares pledged or
Name of shareholders	at the end of	restricted	locked up	Capacity
(%)
	the period	shares held	Status	Number
SHANGHAI FOSUN HIGH	938,095,290	36.60	0	None	0	Domestic non-
TECHNOLOGY (GROUP)						state owned legal
COMPANY LIMITED*						entity
HKSCC NOMINEES LIMITED (Note 1)	551,060,098	21.50	0	Unknown	-	Unknown
CHINA SECURITIES FINANCE	38,736,157	1.51	0	None	0	State owned legal
CORPORATION LIMITED						entity
HONG KONG SECURITIES CLEARING	33,849,388	1.32	0	None	0	Unknown
COMPANY LIMITED (Note 2)
CHINA LIFE INSURANCE COMPANY	26,772,761	1.04	0	None	0	Others
LIMITED - TRADITIONAL -
ORDINARY INSURANCE PRODUCT
- 005L - CT001 SHANGHAI*
CENTRAL HUIJIN ASSET	24,067,700	0.94	0	None	0	State owned legal
MANAGEMENT LTD.*						entity
ABU DHABI INVESTMENT	18,510,795	0.72	0	None	0	Overseas legal
AUTHORITY						entity
TAIKANG LIFE INSURANCE CO., LTD.	10,569,000	0.41	0	None	0	Others
- DIVIDEND - INDIVIDUAL
DIVIDEND - 019L - FH002
SHANGHAI*
CENTRAL BANK OF MALAYSIA	8,766,765	0.34	0	None	0	Unknown
INDUSTRIAL AND COMMERCIAL	8,717,381	0.34	0	None	0	Others
BANK OF CHINA - SSE 50 TRADED
OPEN-END INDEX SECURITIES
INVESTMENT FUND*

- 4 -